Ignite Creation Date:
2024-05-06 @ 2:24 AM
Last Modification Date:
2024-10-26 @ 11:17 AM
Study NCT ID:
NCT02032810
Status:
COMPLETED
Last Update Posted:
2023-01-20
First Post:
2014-01-08
Brief Title:
Phase I of Histone Deacetylase HDAC Inhibitor Panobinostat With Ipilimumab With Unresectable IIIIV Melanoma
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase 1 Study of HDAC Inhibitor Panobinostat LBH 589 Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out if an investigational drug called panobinostat can be given safely with another drug called ipilimumab Investigators want to learn more about the side effects of this combination of drugs using different doses of panobinostat and the same dose of ipilimumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None